Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Express Scripts Excludes Valeant, Eli Lilly Drugs from New Formulary List

By Ryan Bushey | August 3, 2016

Express Scripts posted its new formulary list on Monday, which is a run-down of the drugs it plans to cover under its insurance plan for the following year.

The pharmacy benefits manager decided to exclude 85 drugs from this list for 2017. That figure is slightly smaller than the 87 that were left off it in 2016.

Some of the notable omissions from this list include Valeant Pharmaceutical’s actinic keratosis cream Zyclara, Bristol-Myers Squibb’s arthritis treatment Orencia, as well as Eli Lilly’s psoriasis therapy Taltz, reported Reuters. A spokesperson for Express Scripts, David Whitrap, told the publication the expensive hepatitis C drugs Epclusa and Harvoni will remain on the excluded list, but their status could change by the end of the year.

Also, two arthritis drugs made by Pfizer along with another set of asthma treatments developed by GlaxoSmithKline will be added to Express Script’s list for 2017. They will be considered “preferred alternatives” after price negotiations were conducted between the pharmacy benefits manager and the companies, according to Reuters.

The idea behind removing certain drugs from this list could give Express Scripts more bargaining power when it comes to drug pricing and save money for individual insurers and corporate customers. This program may help participants save an estimated $1.8 billion next year, according to Express Scripts.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE